Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Leukogene Therapeutics Inc
Profile last edited on: 3/6/2023      CAGE: 6T1N7      UEI: DDD1BU62TM94

Business Identifier: Novel drug discovery and development in hematologic malignancies
Year Founded
2012
First Award
2013
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

25 Hunters Hill Drive
Morgantown, PA 19543
   (215) 272-5203
   N/A
   N/A
Location: Single
Congr. District: 06
County: Berks

Public Profile

Leukogene Therapeutics, Inc. operates as an oncology drug discovery and development company focused on developing treatments for patients with incurable blood cancers like Multiple Myeloma.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
1
Conversion Rate
25.00%
Phase I Dollars
$1,481,523
Phase II Dollars
$2,000,000
Total Awarded
$3,481,523

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,454,437
Project Title: AGR2-Superantigen Vaccine Conjugate for the Treatment of Pancreaticductal Adenocarcinoma
2021 1 NIH $362,118
Project Title: Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinoma
2019 2 NIH $2,222,958
Project Title: Proteasome Inhibitor Re-Sensitizing Molecules for Treatment of Refractory Multiple Myeloma
2013 1 NIH $224,701
Project Title: Inhibitors of Igh Gene Enhancers for the Treatment of Multiple Myeloma

Key People / Management

  Frank W Marcoux

  Nathan G Dolloff -- Principal

  Reeder Robinson

Company News

There are no news available.